Zu den Inhalten springen

Publikationen

Originalarbeiten

  • Hoffmann JC, Bahr MJ, Tietge UJF, Braunstein J, Bayer B, Böker KHW, Manns MP. Detection of a soluble form of the human adhesion receptor lymphocyte function-associated antigen-3 (LFA-3) in patients with chronic liver disease. J Hepatol 1996; 25: 465-473.
  • Bahr MJ, Clark IM, Iredale JP, Arthur MJP, Mann DA. Mapping of cis-acting regions of the human TIMP-1 promoter in freshly isolated and culture activated hepatic stellate cells. Cells of the Hepatic Sinusoid 1997; 6: 18-21.
  • Böker KHW, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C, Oldhafer K, Bode U, Pichlmayr R, Manns MP. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203-210.
  • Clark IM, Rowan AD, Edwards DR, Bech-Hansen T, Mann DA, Bahr MJ, Cawston TE. Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochem J 1997; 324: 611-617.
  • Bahr MJ, Böker KHW, Horn W, Günzler V, Manns MP. Serum laminin P1 levels do not reflect critically elevated portal pressure in patients with liver cirrhosis. Hepatogastroenterology 1997; 44: 1200-1205.
  • Tietge UJF, Böker KHW, Bahr MJ, Weinberg S, Pichlmayr R, Schmidt HHJ, Manns MP. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998; 45: 2255-2260.
  • Bahr MJ, Vincent KJ, Arthur MJ, Fowler AV, Smart DE, Wright MC, Clark IM, Benyon RC, Iredale JP, Mann DA. Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulation by activator protein-1 DNA binding proteins. Hepatology 1999; 29: 839-848.
  • Elsharkawy AM, Wright MC, Hay RT, Arthur MJP, Hughes T, Bahr MJ, Degitz K, Mann DA. Persistent activation of NF-kB in cultured rat hepatic stellate cells involves the induction of potentially novel rel-like factors and prolonged changes in the expression of IkB family proteins. Hepatology 1999; 30: 761-769.
  • Rudolph KL, Trautwein C, Kubicka S, Rakemann T, Bahr MJ, Sedlaczek N, Schuppan D, Manns MP. Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. Hepatology 1999; 30: 1159-1166.
  • Lichtinghagen R, Huegel O, Seifert T, Haberkorn CI, Michels D, Flemming P, Bahr M, Boeker KHW. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000; 46: 183-192.
  • Böker KHW, Franzen A, Wrobel M, Bahr MJ, Tietge U, Manns MP. Regulation of hepatic blood flow in patients with liver cirrhosis and after liver transplantation. Pathophysiology 2000; 6: 251-260.
    Barkmann A, Nashan B, Schmidt HHJ, Böker KHW, Emmanouilidis N, Rosenau J, Bahr MJ, Hoffmann MW, Manns MP, Klempnauer J, Schlitt HJ. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolat mofetil. Transplantation 2000; 69: 1886-1890.
  • Böker KHW, Pehle B, Steinmetz C, Breitenstein K, Bahr M, Lichtinghagen R. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogastroenterology 2000; 47: 812-819.
  • Clark IM, Bigg HF, Rowan AD, Edwards DR, Mann DA, Bahr MJ, Cawston TE. Regulation of human TIMP-1 gene expression. In: Inhibitors of metalloproteinases in development and disease (Hawkes SP, Edwards DR, Khokha R eds.). Harwood Academic Press, Lausanne, 2000: 33-41.
  • Schlitt HJ, Barkmann A, Böker KHW, Schmidt HHJ, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591.
  • Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, Manns MP, Böker KHW. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 2001; 34: 239-247.
  • Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Böker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation - possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
  • Tietge UJF, Bahr MJ, Manns MP, Böker KHW. Decreased splanchnic oxygen uptake and increased systemic oxygen uptake in cirrhosis are normalized after liver transplantation. Liver Transpl 2001; 7: 1015-1022.
  • Rosenau J, Tillmann HL, Bahr MJ, Trautwein C, Boeker KHW, Nashan B, Klempnauer J, Manns MP. Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. Transpl Proc 2001; 33: 3637-3638.
  • Tietge UJF, Bahr MJ, Manns MP, Böker KHW. Plasma amino acids in cirrhosis and after liver transplantation - Influence of liver function, hepatic hemodynamics and circulating hormones. Clin Transpl 2002; 16: 9-17.
  • Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HHJ, Nashan B, Lang H, Klempnauer J, Manns MP, Boeker KHW. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002; 73: 386-394.
  • Bahr MJ, Rosenau J, Tietge UJF, Caselitz M, Hoffmann MW, Klempnauer J, Böker KHW, Strassburg CP, Manns MP. Immunosuppression and the prognosis of patients suffering from myeloproliferative disorders after liver transplantation. Transpl Proc 2002; 34: 1493-1494.
  • Tietge UJF, Bahr MJ, Manns MP, Böker KHW. Hepatic amino acid metabolism in liver cirrhosis and in the long-term course after liver transplantation. Transpl Int 2003; 16: 1-8.
  • Tietge UJF, Bahr MJ, Manns MP, Böker KHW. Altered alanine plasma levels despite normalized hepatic alanine extraction in the long-term course after liver transplantation. Transplantation 2003; 75: 804-810.
  • Caselitz M, Bahr MJ, Bleck JS, Chavan A, Manns MP, Wagner S, Gebel M. Sonographic criteria for the diagnosis of hepatic involvement in hereditary hemorrhagic telangiectasia (HHT). Hepatology 2003; 37: 1139-1146.
  • Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, Arndt B, Flemming P, Manns MP, Böker KHW. Expression, coordinated regulation and functional role of matrix metalloproteinases in chronic hepatitis C and HCV-induced liver cirrhosis. Clin Sci 2003; 105: 373-382.
  • Bahr MJ, el Menuawy M, Boeker KHW, Musholt PB, Manns MP, Lichtinghagen R. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003; 23: 420-425.
  • Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D. Prometheus® – A new extracorporal system for the treatment of liver failure. J Hepatol 2003; 39: 984-990.
  • Bahr MJ, Schubert J, Bleck JS, Tietge UJF, Boozari B, Klempnauer J, Strassburg CP, Manns MP. Recurrence of Budd-Chiari syndrome after liver transplantation in paroxysmal nocturnal hemoglobinuria. Transpl Int 2003; 16: 890-894.
  • Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J, Nashan B, Manns MP, Strassburg CP. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transpl 2004; 18: 62-69.
  • Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004; 43: 342-349.
  • Tietge UJF, Böker KHW, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered splanchnic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-E89.
  • Tietge UJF, Selberg O, Kreter A, Bahr MJ, Pirlich M, Burchert W, Müller MJ, Manns MP, Böker KHW. Alterations in muscular glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. Liver Transpl 2004; 10: 1030-1040.
  • Attaran M, Schneider A, Grote C, Zwiens C, Flemming P, Gratz KF, Jochheim A, Bahr MJ, Manns MP, Ott M. Regional and transient ischemia / reperfusion injury in the liver improves therapeutic efficacy of allogeneic intraportal hepatocyte transplantation in low-density lipoprotein receptor deficient Watanabe rabbits. J Hepatol 2004; 41: 837-844.
  • Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJP, European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713.
  • Schneider A, Krüger M, Bahr MJ, Rifai K, Manns MP, Meier PN. Akute Pankreatitis nach endoskopischer Duodenalbiopsie. Endo heute 2004; 17: 213-215.
  • Bahr MJ, Beckermann JGP, Rifai K, Gehrmann L, Rosenau J, Klempnauer J, Strassburg CP, Manns MP. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transpl Proc 2005; 37: 1703-1704.
  • Rifai K, Bahr MJ, Cantz T, Klempnauer J, Manns MP, Strassburg CP. Severe hearing loss after liver transplantation. Transpl Proc 2005; 37: 1918-1919.
  • Wedemeyer J, Gratz KF, Soudah B, Rosenthal H, Straßburg C, Terkamp C, Bahr MJ, Manns MP, Gebel MJ, Bleck JS. Splenose – eine wichtige Differenzialdiagnose unklarer abdomineller Raumforderungen bei splenektomierten Patienten. Z Gastroenterol 2005; 43: 1225-1229.
  • Boozari B, Gebel M, Bahr MJ, Manns MP, Strassburg CP, Bleck JS, Klempnauer J, Nashan B. Changes of duplex parameters and splenic size in liver transplant recipients during a long period of observation. World J Gastroenterol 2005; 11: 6787-6791.
  • Rifai K, Kirchner GI, Bahr MJ, Cantz T, Rosenau J, Nashan B, Klempnauer JL, Manns MP, Strassburg CP. A new side effect of immunosuppression: High incidence of hearing impairment after liver transplantation. Liver Transpl 2006; 12: 411-415.
  • Bahr MJ, Ockenga J, Böker KHW, Manns MP, Tietge UJF. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism, but not with insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E199-E206.
  • Kubitschke A, Bahr MJ, Aslan N, Bader C, Tillmann HL, Sarazzin C, Greten T, Wiegand J, Manns MP, Wedemeyer H. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest 2007; 37: 54-64.
  • Potthoff A, Deterding K, Trautwein C, Flemming P, Strassburg CP, Manns MP, Wedemeyer H, Bahr MJ. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol 2007; 45: 15-19.
  • Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, Tillmann HL, Klempnauer J, Strassburg CP, Manns MP. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007; 13: 367-373.
  • Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N, Finger A, Michel G, Nashan B, Kuse ER, Klempnauer J, Tillmann HL, Manns MP. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV-DNA decrease during early immunoglobulin administration. J Hepatol 2007; 46: 635-644.
  • Ockenga J, Tietge UJF, Böker KHW, Manns MP, Brabant G, Bahr MJ. Distinct roles of free leptin, bound leptin and soluble leptin receptor during the metabolic-inflammatory response in patients with liver cirrhosis. Aliment Pharmacol Ther 2007; 25: 1301-1309.
  • Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, MacFarlane M, Cohen GM, Manns MP, Schulze-Osthoff K, Bantel H. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007; 46: 1498-1508.
  • Hadem J, Stiefel P, Bahr MJ, Tillmann HL, Rifai K, Klempnauer J, Wedemeyer H, Manns MP, Schneider AS. Prognostic implications of lactate, bilirubin and etiology in German patients with acute liver failure. Clin Gastroenterol Hepatol 2008; 6: 339-345.
  • Volkmann X, Anstaett M, Hadem J, Stiefel P, Bahr MJ, Lehner F, Manns MP, Schulze-Osthoff K, Bantel H. Caspase activation is associated with spontaneous recovery from acute liver failure. Hepatology 2008; 47: 1624-1633.
  • Schwettmann L, Wehmeier M, Jocovic D, Brand K, Manns MP, Lichtinghagen R, Bahr MJ. Expression of A Disintegrin And Metalloproteinase (ADAM) and ADAMs with Thrombospondin Motives (ADAM-TS) enzymes in chronic liver diseases. J Hepatol 2008; 49: 243-250.
  • Brakensiek K, Frye-Boukhriss H, Mälzer M, Abramowicz M, Bahr MJ, von Beckerath N, Bergmann C, Caselitz M, Holinski-Feder E, Muschke P, Oexle K, Strobl-Wildemann G, Wolff G, El-Harith EA, Stuhrmann M. Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia. Clin Genet 2008; 74: 171-177.
  • Boozari B, Bahr MJ, Kubicka S, Klempnauer J, Manns MP, Gebel M. Ultrasonography in patients with Budd-Chiari syndrome – Diagnostic signs and prognostic implications. J Hepatol 2008; 49: 572-580.
  • Bahr MJ, Boeker KHW, Manns MP, Tietge UJF. Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but not associated with insulin resistance in patients with liver cirrhosis. Clin Endocrinol 2009; 70: 60-65.
  • de Boer JF, Bahr MJ, Böker KHW, Manns MP, Tietge UJF. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G196-201.
  • Kielstein JT, Hesse G, Bahr MJ, Tsikas D, Terkamp C, Martens-Lobenhoffer J, Manns MP, Haller H, Panning B, Bode-Böger SM, Gebel M. Procedure-related pulmonary hypertension in patients with hepatocellular carcinoma undergoing percutaneus ethanol injection – Role of ethanol, hemolysis, asymmetric demethylarginine, and the nitric oxide system. Crit Care Med 2009; 37: 1483-1485.
  • Deterding K, Pothakamuri SV, Schlaphoff V, Hadem J, Metzler F, Bahr MJ, Manns MP, Cornberg M, Wedemeyer H. Clearance of chronic HCV infection during acute delta hepatitis. Infection 2009; 37: 159-162.
  • Murad SD, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HLA for the European Network for Vascular Disorders of the Liver (EN-Vie). Risk factors, management and outcome of Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-175.
  • Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, Bahr MJ. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009; im Druck.
  • Deterding K, Grüngreiff K, Lankisch TO, Potthoff A, Bahr MJ, Manns MP, Wedemeyer H, Strassburg CP. Antiviral therapy for chronic hepatitis C in patients with Gilbert’s syndrome: Unexpected side effects and decision making. Ann Hepatol 2009; im Druck.
  • Tutarel O, Barg-Hock H, Pischke S, Bahr MJ, Kreipe HH, Greten TF, Manns MP, Strassburg CP. Mycosis fungoides with involvement of the larynx after liver transplantation in an adult. Am J Gastroenterol 2009; im Druck.
  • Beckmann MG, Bahr MJ, Hadem J, Bredt M, Wedemeyer H, Schneider AS, Kubicka S, Manns MP, Strassburg CP, Wedemeyer J. Clinical relevance of transjugular liver biopsy in comparison to percutaneous and laparoscopic liver biopsy. Gastroenterol Res Pract 2009; im Druck.
  • Pischke S, Ehmer U, Schedel I, Gratz WF, Wedemeyer H, Ziesing S, Bange FC, Burchard GD, Manns MP, Bahr MJ, Strassburg CP. Of Guinea pigs and men – An unusual case of jaundice. Z Gastroenterol 2009; im Druck.

Übersichten, Buchkapitel

  • Bahr MJ, Manns MP. Leberzirrhose. Internist 1999; 40: 1308-1322.
  • Rehermann B, Bahr MJ, Manns MP. Pathophysiologie der Entzündung und der Fibrose. In: Klinische Gastroenterologie und Stoffwechsel (Adler G, Beglinger C, Manns MP, Müller-Lissner S, Schmiegel W eds.). Springer-Verlag, Heidelberg, 2000: 391-405.
  • Tillmann H, Bahr MJ, Böker KHW, Manns MP. Hepatitis B/C beim Organspender und Transplantatempfänger. TransplantLink 2000; 2: 40-47.
  • Bahr MJ, Böker KHW, Manns MP. Hepatitis C und Lebertransplantation. Bundesgesundheitsbl 2001; 44: 572-577.
  • Bahr MJ, Manns MP. Funktion des Immunsystems bei Leberzirrhose. Z Gastroenterol 2001; 39: 601-607.
  • Bahr MJ, Manns MP. Azathioprin in der Transplantationsmedizin. In: Azathioprin in der Gastroenterologie (Gross M ed.). UNI-MED Verlag, Bremen, 2002: 77-86.
  • Bahr MJ, Böker KHW, Manns MP. Lebertransplantation und Anschlusstherapie. In: Medizinische Therapie in Klinik und Praxis (Schölmerich J ed.). Springer Verlag, Heidelberg, 2003: 898-900.
  • Rifai K, Bahr MJ. Akutes Leberversagen. Internist 2003; 44: 585-598.
  • Bahr MJ, Böker KHW. Lebertransplantation bei Hepatitis C. In: Handbuch Hepatitis C: Diagnostik, Verlauf, Therapie (Manns MP, Wedemeyer H eds.). UNI-MED Verlag, Bremen, 2003: 96-104.
  • Bahr MJ, Böker KHW, Manns MP. Lebertransplantation. In: Classen Diehl Kochsiek - Innere Medizin, 5. Aufl. (Berdel WE, Böhm M, Classen M, Diehl V, Kochsiek K, Schmiegel W eds.). Urban & Fischer Verlag, München, 2003: 184-189.
  • Bahr MJ, Böker KHW, Manns MP. Lebertransplantation. In: Classen Diehl Kochsiek – Repetitorium Innere Medizin, 1. Aufl. (Berdel WE, Böhm M, Classen M, Diehl V, Kochsiek K, Schmiegel W eds.). Urban & Fischer Verlag, München, 2003: 32-33.
  • Rifai K, Ott M, Bahr MJ, Schneider A, Manns MP. Leberersatztherapie – Gesicherte Indikationen bei akutem Leberversagen. Internist 2003; 44: 1485-1490.
  • Rifai K, Bahr MJ, Schneider A, Ott M, Manns MP. Neue Verfahren in der Leberersatztherapie. Med Klin 2003; 98: 750-753.
  • Bahr MJ, Manns MP. Hepatitis-C-Reinfektion nach Lebertransplantation: Natürlicher Verlauf und therapeutische Strategien. Lebenslinien 2004 (2); 7-9.
  • Rifai K, Manns MP, Bahr MJ. Lebertransplantation bei metabolischen Lebererkrankungen im Erwachsenenalter. Z Gastroenterol 2004; 42: 749-765.
  • Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diagn 2004; 4: 715-726.
  • Manns MP, Bahr MJ. Recurrent hepatitis C after liver transplantation: Natural course and treatment strategies. In: Immunology and the liver: Immunotherapy (Moreno-Otero R, Albillos A, Banares R, Cuervas-Mons V, Medina J eds.). Acción Médica, Madrid, 2004: 361-371.
  • Bahr MJ, Manns MP. Treatment of chronic HCV infection in compensated and decompensated cirrhosis. J Gastroenterol Hepatol 2004; 19 Suppl. 7: S94-S98.
  • Bahr MJ. Akute Dekompensation einer Leberzirrhose mit hepatischer Enzephalopathie. Intern Prax 2005; 45: 310-312.
  • Bahr MJ, Böker KHW, Manns MP. Lebertransplantation und Anschlusstherapie. In: Medizinische Therapie 2005 | 2006, 2. Aufl. (Schölmerich J ed.). Springer Verlag, Heidelberg, 2005: 844-845.
  • Wedemeyer J, Malek NP, Manns MP, Bahr MJ. Molekulare Therapie in der Gastroenterologie und Hepatologie. Internist 2005; 46: 861-872.
  • Bahr MJ, Manns MP. Immunsuppressive Therapie. In: Intensivmedizin, 2. Aufl. (Van Aken H, Reinhart K, Zimpfer M, Welte T eds.). Georg Thieme Verlag, Stuttgart, 2006: 1484-1487.
  • Bahr MJ. Lebertransplantation bei Hepatitis C. In: Handbuch Hepatitis C: Diagnostik, Verlauf, Therapie, 2. Aufl. (Manns MP, Wedemeyer H eds.). UNI-MED Verlag, Bremen, 2006: 119-131.
  • Manns MP, Bahr MJ, Bantel H. Autoimmune hepatitis. In: Schiff’s Diseases of the Liver, 10th ed. (Schiff ER, Sorrell MF, Maddrey WC eds.). Lippincott Williams & Wilkins, Philadelphia, 2006: 865-874.
  • Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP. Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-)Infektion. “Upgrade” der Leitlinie, AMWF-Register-Nr.: 021/011. Z Gastroenterol 2007; 45: 525-74.
  • Bahr MJ, Böker KHW, Manns MP. Lebertransplantation und Anschlusstherapie. In: Medizinische Therapie 2007 | 2008, 3. Aufl. (Schölmerich J ed.). Springer Verlag, Heidelberg, 2007: 930-931.
  • Bahr MJ. Nichtinvasive und invasive Diagnostik des Fibrosestadiums bei Patienten mit Virushepatitis. In: Virushepatitis als Berufskrankheit - Ein Leitfaden zur Begutachtung, 3. Aufl. (Selmair H, Manns MP eds.). Ecomed MEDIZIN Verlag, Landsberg, 2007: 57-69.
  • Strassburg CP, Bahr MJ, Becker T, Klempnauer J, Manns MP. Fortschritte in der Immunsuppression. Chirurg 2008; 79: 149-156.
  • Bahr MJ, Boozari B. An unusual case of ascites (Online Tutorial) Gut 2008; 57: 467.
  • Bahr MJ, Wedemeyer J. Leitsymptom Erbrechen – Differenzialdiagnostik für den Notarzt. Notfall & Hausarztmedizin 2008; 34: 120-125.
  • Bahr MJ, Manns MP. Interferontherapie bei Hepatitis C – Von den Anfängen in die Zukunft. Lebenslinien 2008; 02-08: 15-17.
  • Bahr MJ. Nichtinvasive Leberfibrosebestimmung. Med Welt 2009; 60: 137-142.
  • Bahr MJ. Lebertransplantation bei Hepatitis C. In: Handbuch Hepatitis C: Diagnostik, Verlauf, Therapie, 3. Aufl. (Manns MP, Wiegand J, Wedemeyer H eds.). UNI-MED Verlag, Bremen, 2009: im Druck.
  • Bahr MJ. Das hepatorenale Syndrom. Spektrum der Nephrologie 2009; im Druck.

Editorials, Kommentare

  • Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation - When non-self becomes self (Editorial). Hepatology 2000; 32: 868-870.
  • Bahr MJ, Rosenau J, Manns MP. Discussion on the association between hepatitis C infection and survival after orthotopic liver transplantation (Letter). Gastroenterology 2002; 123: 2160.
  • Bahr MJ, Manns MP. Recurrent hepatitis C in transplanted patients: more questions than answers (Editorial). Dig Liver Dis 2003; 35: 2-6.
  • Bahr MJ, Manns MP. Changing faces – Natural course and treatment of hepatitis C after liver transplantation (Editorial). J Hepatol 2004; 40: 699-701.
  • Bahr MJ, Schneider AS. Sekundärprävention der koronaren Herzkrankheit: Allgemeinmaßnahmen plus Medikamente (Leserbrief). Dt Ärztebl 2006; 103: A346-347.
  • Bahr MJ. Budd-Chiari-Syndrom. Results from the European Network for Vascular Disorders of the Liver (EN-Vie) (Kommentar). Hep-Net News 2007; 1: 14.
  • Manns MP, Bahr MJ. Gastrointestinale Leitsymptome (Editorial). Notfall & Hausarztmedizin 2008; 34: 119.
  • Hadem J, Stiefel P, Bahr MJ, Wedemeyer H, Manns MP, Schneider AS. Reply to “Prognostic implications of lactate, bilirubin and etiology in German patients with acute liver failure” (Kommentar). Clin Gastroenterol Hepatol 2009; 7: 249.
  • Bantel H, Bahr MJ, Schulze-Osthoff K. An apoptosis biomarker for prediction of nonalcoholic steatohepatitis (Letter). Hepatology 2009; 50: 991.
Kontakt
Sana Kliniken Lübeck
Kronsforder Allee 71-73
23560 Lübeck

Telefon: 0451 585-01
Telefax: 0451 585-1234
Übersichtsbroschüre